The chart below provides an indication of the relative R&D spend of the top fifty bigpharma companies worldwide.
This chart is updated annually. Last updated: 12 September 2011.
Source: Current Agreements, 2011
Source: Current Agreements, 2011
R&D spending
- Cephalon: Company Profile
- Warner Chilcott: Company Profile
- Alcon: Company Profile
- Shire: Company Profile
- Biogen Idec: Company Profile
- Top twenty partnering deals of 2011 have a combined value of over $21 billion
- Vical and Teva Pharmaceutical establish sales and marketing agreement for Allovectin-7(r) in Israel
- Biopharma partnering: Perspectives from BCG’s latest biotech and pharma partnering study
- Biotech investing at a crossroads?
- Medtronic sells defibrillator unit to Bain Capital for $487 million
- tom squitt: Watson and Amgen are trying to take over the Biote...
- Claire Nicholson: Hello Pamela, thanks for your message! If you clic...
- Steve Poile: Thanks for your comment. Of course, I agree with...
- David Scott: Nice summary Steve. Notwishstanding that the headl...
- Pamela Agner: Please send an e-copy of Biopharma partnering: Per...
Home | Reports | Services | Insight | News | Events | Scorecard | About us | Terms & conditions | Subscribe | Contact us
© 2012 Wildwood Ventures Ltd. 